{"entity":{"id":"precigen","kind":"company","name":"Precigen","aka":["Intrexon"],"tldr":"Precigen is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing the adenoviral immunotherapies PRGN-2012 (Papzimeos) and PRGN-2009 in rare cancers of childhood and cervical cancer.","summary":"Precigen is a commercial-stage biopharmaceutical company developing precision medicines for difficult-to-treat diseases. Its first approved product, Papzimeos (zopapogene imadenovec, formerly PRGN-2012), is an adenoviral immunotherapy for recurrent respiratory papillomatosis; PRGN-2009 for HPV-associated cancers and the UltraCAR-T programmes are in phase 1. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT04724980 (phase 1/2, Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis) and NCT06157151 (phase 2, PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Ce...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://precigen.com"},{"label":"ClinicalTrials.gov: trials led by Precigen","url":"https://clinicaltrials.gov/search?lead=Precigen%2C%20Inc"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["rare-childhood-cancers","cervical"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04724980","nct06157151"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Germantown, Maryland","country":"US","companyType":"biotech","website":"https://precigen.com","ticker":"NASDAQ:PGEN","stage":"public","investors":[],"funding":[]},"route":"/companies/precigen/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"rare-childhood-cancers","kind":"cancer","name":"Rare cancers of childhood (NCI PDQ umbrella)","route":"/cancers/rare-childhood-cancers/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"trial":[{"id":"nct04724980","kind":"trial","name":"Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis","route":"/trials/nct04724980/"},{"id":"nct06157151","kind":"trial","name":"PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06157151/"}]}}